It has huge potential. We already see a company like Manulife saying, “We will wait for CADTH to make a decision before we fund some of these drugs.” Well, okay, are you going to fund CADTH to do that as well? Quite frankly, we don't think CADTH is looking at the same criteria as the private plans are, so if you are going to do that, you are going to have to expand it.
We would rather see a single body that can do that. There is no doubt about it. Whether there will still be private funders, I think that is a different question.
Germany has public and private plans, but they have one HTA system. They have one national registry. They have one monitoring system in order to collect that information.
At the end of the day, who puts their money into a plan in order to get the benefits from it is very different from who should actually have an overarching plan that would make the recommendations about drugs and how they are going to be monitored, and have—as I think everybody says—a combined registry that would allow us to track all that information.
At the end of the day, if there are some private plans that are going to be funding differently and people want to buy into those.... I don't know enough about it to make a real recommendation, but all the things we are saying.... I think having a national system that would actually do that is essential, especially for rare diseases.